ArticleBritish journal of cancer2003
Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura.
Article in British journal of cancer, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 0 citations in OpenAlex.
- Matrix Metalloproteinases as Biomarkers and Treatment Targets in Mesothelioma: A Systematic Review.Biomolecules · 2021Pooled it
- Proteasomal degradation of polycomb-group protein CBX6 confers MMP-2 expression essential for mesothelioma invasion.Scientific reports · 2020Article
- Review
- The Immune Microenvironment in Mesothelioma: Mechanisms of Resistance to Immunotherapy.Frontiers in oncology · 2019Review
- Matrix Metalloproteinases Polymorphisms as Prognostic Biomarkers in Malignant Pleural Mesothelioma.Disease markers · 2017Article
- Overexpression of micro ribonucleic acid-591 inhibits cell proliferation and invasion of malignant pleural mesothelioma cells.Thoracic cancer · 2016Article
- Reactive oxygen species a double-edged sword for mesothelioma.Oncotarget · 2015Review
- Modulation of u-PA, MMPs and their inhibitors by a novel nutrient mixture in human lung cancer and mesothelioma cell lines.International journal of oncology · 2013Article
- Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.British journal of pharmacology · 2012Review
- Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.Clinical cancer research : an official journal of the American Association for Cancer Research · 2012Article
- Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.Oncology letters · 2012Article
- ALCAM regulates motility, invasiveness, and adherens junction formation in uveal melanoma cells.PloS one · 2012Article
- Recombinant GPI-anchored TIMP-1 stimulates growth and migration of peritoneal mesothelial cells.PloS one · 2012Article
- Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application.Cancers · 2010Article
- 3-O-Methylfunicone, a metabolite produced by Penicillium pinophilum, modulates ERK1/2 activity, affecting cell motility of human mesothelioma cells.Cell proliferation · 2010Article
- Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.Journal of cancer research and clinical oncology · 2009Review
- Pathogenesis of malignant pleural mesothelioma and the role of environmental and genetic factors.Journal of carcinogenesis · 2008Article
- Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells.Cancer science · 2008Article
- Biomarkers for malignant pleural mesothelioma: current status.Molecular diagnosis & therapy · 2008Review
- Expression of cancer-associated molecules in malignant mesothelioma.Biomarker insights · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Matrix metalloproteinases (MMPs), in particular the gelatinases (MMP-2 and -9), play a significant role in tumour invasion and angiogenesis. The expression and activities of MMPs have not been characterised in malignant mesothelioma (MM) tumour samples. In a prospective study, gelatinase activity was evaluated in homogenised supernatants of snap frozen MM (n=35), inflamed pleura (IP, n=12) and uninflammed pleura (UP, n=14) tissue specimens by semiquantitative gelatin zymography. Matrix metalloproteinases were correlated with clinicopathological factors and with survival using Kaplan-Meier and Cox proportional hazard models. In MM, pro- and active MMP-2 levels were significantly greater than for MMP-9 (P=0.006, P<0.001). Active MMP-2 was significantly greater in MM than in UP (P=0.04). MMP-2 activity was equivalent between IP and MM, but both pro- and active MMP-9 activities were greater in IP (P=0.02, P=0.009). While there were trends towards poor survival with increasing total and pro-MMP-2 activity (P=0.08) in univariate analysis, they were both independent poor prognostic factors in multivariate analysis in conjunction with weight loss (pro-MMP-2 P=0.03, total MMP-2 P=0.04). Total and pro-MMP-2 also contributed to the Cancer and Leukemia Group B prognostic groups. MMP-9 activities were not prognostic. Matrix metalloproteinases, and in particular MMP-2, the most abundant gelatinase, may play an important role in MM tumour growth and metastasis. Agents that reduce MMP synthesis and/or activity may have a role to play in the management of MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.